In response to allegations from the Federal Trade Commission (FTC) against Amazon, AWS CEO Adam Selipsky discusses AI technology and evaluates Amazon’s endeavors in the U.S. market on FOX Business Originals.
Metrodora Ventures, the venture capital firm founded by Chelsea Clinton, is backing a company that leverages artificial intelligence to accelerate drug development and enhance the accuracy of forecasting clinical trial outcomes.
With a significant $4 million in pre-seed funding spearheaded by Metrodora, the health tech startup BioPhy has recently unveiled its AI operating system, which the company asserts has already delivered impressive outcomes.
Dave Latshaw II, PhD, the co-founder and CEO of BioPhy, shared insights with FOX Business. A seasoned professional, Latshaw founded the company in 2019 following a successful tenure overseeing Johnson & Johnson’s AI medicine development program for six years. He emphasized his pivotal role in deploying the technology from its nascent stages to regulatory approval.
Latshaw, alongside his fellow founders, initially crossed paths during their studies at the Wharton School of the University of Pennsylvania. Collaborating for approximately 18 months, they diligently refined and tested the technology.
CEO Dave Latshaw II, PhD, Fox News / BioPhy
Highlighting the practical application of their program in real-world scenarios, Latshaw underscored the importance of ensuring its efficacy beyond the digital realm, especially in predicting clinical trial outcomes. He expressed pride in the program’s success over the past 2.5 years in achieving this goal.
On October 26, 2015, an employee at Pfizer Inc.’s research and development center in Cambridge, Massachusetts, is captured handling tubes in dry snow. BioPhy’s AI-driven platform has significantly expedited drug development and remarkably enhanced the accuracy of outcome predictions.
Boasting an impressive 80% accuracy rate, BioPhy’s technology has successfully forecasted the results of over 1,500 clinical trials, marking a substantial improvement over traditional methodologies. This advancement enables pharmaceutical companies to potentially save millions in clinical development costs, with the startup already securing partnerships with two of the top five U.S. drug manufacturers.
Upon being introduced to the founders through a mutual network at Wharton, Metrodora, known for its investments in early-stage health care and education startups, swiftly recognized the potential of BioPhy’s groundbreaking technology.
Metrodora’s Managing Partner, Caroline Kassie, emphasized the critical need for swift and efficient drug development in today’s landscape. She highlighted the significance of leveraging AI technology to enhance success rates in medical studies, projecting a substantial increase in new therapies over the next decade.
Kassie expressed enthusiasm about collaborating with Dave and the dedicated team at BioPhy to realize this ambitious vision.
